News Releases Year None20202019201820172016 BridgeBio Pharma and Affiliate Navire Pharma Announce Dosing of First Patient in Phase 1 Clinical Trial of SHP2 inhibitor BBP-398 for Tumors Driven by RAS and Receptor Tyrosine Kinase Mutations 11.13.2020 BridgeBio Pharma, Inc. Reports Third Quarter 2020 Financial Results And Business Update 11.05.2020 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 11.04.2020 BridgeBio Pharma and Affiliate Phoenix Tissue Repair Announce First Patient Dosing In Phase 2 Trial of Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) 10.27.2020 BridgeBio Pharma, Inc. and the University of Colorado Anschutz Medical Campus Collaborate to Advance Medicines for Genetically Driven Diseases 10.21.2020 Salk Institute and BridgeBio Pharma Collaborate to Advance Therapies for Genetically Driven Disease 10.21.2020 BridgeBio Pharma and Eidos Therapeutics Announce Merger Agreement 10.05.2020 BridgeBio Pharma and Affiliate Origin Biosciences Announces FDA Acceptance of its New Drug Application for Fosdenopterin for the Treatment of MoCD Type A 09.29.2020 BridgeBio Pharma to Host Virtual R&D Day on September 29, 2020 09.22.2020 BridgeBio Pharma’s Calcilytix Therapeutics Initiates Phase 2 Study Of Encaleret For Autosomal Dominant Hypocalcemia Type 1 (ADH1) 09.21.2020 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 09.03.2020 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 08.12.2020 BridgeBio Pharma, Inc. Reports Second Quarter 2020 Financial Results and Business Update 08.11.2020 BridgeBio Pharma Expands Reach Into China and Other Major Asian Markets Through Strategic Collaboration With Perceptive Advisors-Founded Company, LianBio 08.11.2020 Ivy Brain Tumor Center and BridgeBio Pharma’s QED Therapeutics Announce Dosing of First Patient in Investigator-Initiated Phase 0/2 Clinical Trial of Infigratinib in Recurrent Glioblastoma 07.28.2020 BridgeBio Pharma’s QED Therapeutics Doses First Child in Phase 2 Clinical Trial of the Investigational Medicine Infigratinib in Achondroplasia 07.15.2020 BridgeBio Pharma’s Phoenix Tissue Repair to Highlight Interim Phase 1/2 Study Data in a Presentation at the Society for Pediatric Dermatology’s 45th Annual Meeting 07.10.2020 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 07.06.2020 BridgeBio Pharma, Inc. Appoints Biotech Trailblazers Brent Saunders and Randy Scott and Renowned Economist Andrew Lo to Board of Directors 06.24.2020 BridgeBio Pharma and University of Florida Establish Collaboration to Advance Therapies for Genetically Driven Diseases 06.18.2020 BridgeBio Pharma, Inc. Enters Into Collaboration Agreement With Johns Hopkins University to Accelerate Development of New Medicines in Genetically Driven Diseases 06.18.2020 BridgeBio Pharma’s ML Bio Solutions Announces Dosing of First Subject in Phase 1 Clinical Trial of BBP-418 For Limb Girdle Muscular Dystrophy Type 2i (LGMD2i) 06.11.2020 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 06.05.2020 BridgeBio Pharma’s QED Therapeutics Presents Data on Infigratinib in Cholangiocarcinoma and Urothelial Carcinoma at the American Society of Clinical Oncology 2020 Virtual Scientific Program 05.29.2020 BridgeBio Pharma’s Phoenix Tissue Repair Provides Updates to its Recessive Dystrophic Epidermolysis Bullosa (RDEB) Program and Announces New Leadership Appointments 05.13.2020 BridgeBio Pharma, Inc. Reports First Quarter 2020 Financial Results and Business Update 05.13.2020 BridgeBio Pharma’s QED Therapeutics Announces Preclinical Data Demonstrating Potential of Low-Dose Infigratinib in Achondroplasia 05.11.2020 BridgeBio Pharma, Inc. To Present At Upcoming Investor Conference 05.06.2020 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 05.05.2020 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 04.03.2020 BridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations 03.12.2020 BridgeBio Pharma, Inc. Prices Upsized Offering of $475 Million Convertible Senior Notes 03.04.2020 BridgeBio Pharma, Inc. Announces Proposed Offering of $350 Million Convertible Senior Notes 03.04.2020 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 03.03.2020 BridgeBio Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Portfolio Progress 03.02.2020 BridgeBio Pharma, Inc. Appoints Ronald J. Daniels To Its Board of Directors 02.24.2020 BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences 02.21.2020 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 02.05.2020 BridgeBio Pharma Grows Pipeline to 20+ Genetic Medicines with Four Assets Focused on Treating Genetically Driven Diseases at Their Source 01.13.2020 BridgeBio Pharma’s Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity 01.10.2020 PellePharm Initiates Phase 2 Clinical Trial of Patidegib Topical Gel for People With High Frequency Basal Cell Carcinoma 01.08.2020 BridgeBio Pharma’s QED Therapeutics Receives Fast Track Designation for Infigratinib in Adults with First-Line Advanced or Metastatic Cholangiocarcinoma and Orphan Drug Designation for Infigratinib for Treatment of Cholangiocarcinoma 01.06.2020
